Brokerages Set STAAR Surgical (NASDAQ:STAA) PT at $43.33

STAAR Surgical (NASDAQ:STAA) has received a consensus recommendation of “Hold” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $43.33.

A number of brokerages recently issued reports on STAA. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, October 31st. Stifel Nicolaus reduced their price objective on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, August 26th. Finally, Canaccord Genuity Group decreased their target price on STAAR Surgical from $41.00 to $31.00 and set a “hold” rating for the company in a report on Friday, November 1st.

STAAR Surgical Trading Down 0.9 %

NASDAQ STAA opened at $26.14 on Friday. STAAR Surgical has a 12-month low of $26.02 and a 12-month high of $52.68. The company has a fifty day simple moving average of $31.14 and a two-hundred day simple moving average of $36.96. The stock has a market cap of $1.29 billion, a P/E ratio of 59.41 and a beta of 0.61.

Hedge Funds Weigh In On STAAR Surgical

Several institutional investors and hedge funds have recently modified their holdings of STAA. Van ECK Associates Corp lifted its stake in shares of STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 393 shares during the period. Sei Investments Co. raised its position in shares of STAAR Surgical by 2.7% in the second quarter. Sei Investments Co. now owns 15,087 shares of the medical instruments supplier’s stock worth $718,000 after acquiring an additional 394 shares during the period. Creative Planning boosted its stake in shares of STAAR Surgical by 8.0% during the 3rd quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock worth $205,000 after acquiring an additional 408 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of STAAR Surgical by 3.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,343 shares of the medical instruments supplier’s stock valued at $540,000 after acquiring an additional 418 shares during the period. Finally, Linden Thomas Advisory Services LLC increased its stake in shares of STAAR Surgical by 2.3% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 20,721 shares of the medical instruments supplier’s stock valued at $987,000 after purchasing an additional 469 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.